Atossa Therapeutics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more
Atossa Therapeutics Inc (YAG2) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.121x
Based on the latest financial reports, Atossa Therapeutics Inc (YAG2) has a cash flow conversion efficiency ratio of -0.121x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.00 Million) by net assets (€49.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Atossa Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Atossa Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Atossa Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atossa Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Openedges Tech Inc
KQ:394280
|
N/A |
|
Fenix Resources Limited
F:4ER
|
N/A |
|
THONBURI HEALTHCARE GRO-NVDR
BK:THG-R
|
N/A |
|
Park City Group Inc
F:PJ4A
|
0.031x |
|
Cogelec SA
PA:ALLEC
|
0.282x |
|
Hanover Bancorp Inc
NASDAQ:HNVR
|
0.014x |
|
Nordhealth AS
OL:NORDH
|
-0.008x |
|
LuxUrban Hotels Inc. 13.00% Series A Cumulative Redeemable Preferred Stock
NASDAQ:LUXHP
|
0.756x |
Annual Cash Flow Conversion Efficiency for Atossa Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Atossa Therapeutics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €71.48 Million | €-21.03 Million | -0.294x | -34.61% |
| 2023-12-31 | €91.02 Million | €-19.89 Million | -0.219x | -24.20% |
| 2022-12-31 | €117.96 Million | €-20.76 Million | -0.176x | -47.58% |
| 2021-12-31 | €138.14 Million | €-16.47 Million | -0.119x | +72.00% |
| 2020-12-31 | €27.17 Million | €-11.57 Million | -0.426x | +38.62% |
| 2019-12-31 | €13.16 Million | €-9.13 Million | -0.694x | +31.83% |
| 2018-12-31 | €8.81 Million | €-8.96 Million | -1.018x | -7.10% |
| 2017-12-31 | €6.94 Million | €-6.59 Million | -0.950x | +45.24% |
| 2016-12-31 | €3.10 Million | €-5.37 Million | -1.735x | -- |